Riskpilot← Back to searchSign inGet full accessGloriosa medical AB
ABActiveOrg 5591336085Södra Vägen 68 AMedical specialists activities · NACE 8622Est. 20170 employees
Revenue 2024
SEK 88K
+24% vs 2023
EBITDA margin
65.8%
-9% vs 2023
Equity ratio
89.3%
Financial strength
Net profit 2024
SEK 46K
-11% vs 2023
| Revenue | SEK 88K | +24% |
| EBITDA | SEK 58K | -9% |
| Net profit | SEK 46K | -11% |
| Total assets | SEK 243K | +29% |
| Equity | SEK 217K | +27% |
| Employees | 0 | — |
Legal name
Gloriosa medical AB
Org number
5591336085
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
13 november 2017
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall verka som legitimerad läkare med konsultuppdrag inom medicin och läkarverksamhet, arbete såväl i hemmet som på annat sjukhus och vårdcentral samt därmed förenlig verksamhet.
Address
Södra Vägen 68 A
Email
katrinrabie@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 113 | 4 | 0 | 71 | 88 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 108 | −3 | −4 | 64 | 58 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | — |
| EBIT | 108 | −3 | −4 | 64 | 58 |
| Net financials | — | −1 | — | — | 0 |
| Profit before tax | 108 | −3 | −4 | 64 | 58 |
| Tax | −22 | −0 | −0 | −12 | −12 |
| Net profit | 86 | −3 | −4 | 52 | 46 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 192 | 153 | 124 | 189 | 243 |
| Equity | 127 | 123 | 119 | 171 | 217 |
| Long-term debt | 0 | 0 | 0 | 0 | — |
| Short-term debt | 65 | 29 | 5 | 17 | 26 |
| Total debt | 65 | 29 | 5 | 17 | 26 |
EBITDA margin
65.8%
This company
15.8%
Market median
+316% vs market
20202024
Equity ratio
89.3%
This company
38.2%
Market median
+134% vs market
20202024
Return on equity
21.2%
This company
18.4%
Market median
+15% vs market
20202024
Net profit margin
52.4%
This company
8.1%
Market median
+547% vs market
20202024
Asset turnover
0.36×
This company
1.12×
Market median
-68% vs market
20202024
Debt / equity
0.12×
This company
0.62×
Market median
+81% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
LÅ Audit | Audit | 2022 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Gloriosa medical AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars Åke Ahlert | Audit | 0 companies |
| Katrin Khatereh Maria Rabiei Tabriz | Board of Directors | 0 companies |
| Shahnaz Mansouri Bakhsh | Deputy Board Member | 0 companies |